Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$1.33B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.24B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.43B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.20B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.45B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.46B
Gross Margin
98.97%
TTM Avg
9.74%
3Y Avg
-353.69%
5Y Avg
-246.22%
Market Cap
$1.16B
Gross Margin
88.05%
TTM Avg
93.34%
3Y Avg
92.32%
5Y Avg
92.94%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | 0.00% | 0.00% | 0.00% | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | 0.00% | 0.00% | 0.00% | 0.00% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 36.16% | 31.39% | 23.56% | 1.95% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | 0.00% | 0.00% | 0.00% | 0.00% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 17.33% | 13.16% | 12.65% | 13.31% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 98.97% | 9.74% | -353.69% | -246.22% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 88.05% | 93.34% | 92.32% | 92.94% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
